These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.

A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right ...

Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial ...

Pfizer's NYSE Composite context covers pharmaceutical operations, Tukysa approval, oncology research, vaccine development, patent exclusivity and dividend commitments across global healthcare markets.

Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at ...

Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

Relay is rated Hold despite a 175% rally, given overvaluation relative to a risk-adjusted fair value of $13.53 per share.

The Department of Defense awarded a nearly $41 million contract earlier this year to a Singapore-based drug company to develop a novel ketamine product to treat severe pain incurred in battle — but ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ...